CORRECTION: RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution

Core Insights - The FDA has granted expanded clearance for DeepHealth's SmartMammo Dx AI algorithm, allowing compatibility with GE HealthCare's Senographe Pristina mammography systems, enhancing breast cancer detection capabilities [1][2][4] - This collaboration aims to improve breast cancer screening programs by leveraging AI technology to enhance diagnostic accuracy and operational efficiency in radiology workflows [3][5] Company Overview - RadNet, Inc. is a leading provider of diagnostic imaging services in the U.S., operating 399 outpatient imaging centers across multiple states [7] - DeepHealth, a subsidiary of RadNet, focuses on AI-powered health informatics, aiming to improve clinical outcomes and operational efficiency in various health domains, including breast cancer [9] Technology and Impact - SmartMammo Dx has been previously cleared for use with HOLOGIC systems and has supported millions of exams, indicating its effectiveness in enhancing breast cancer detection [4] - The integration of SmartMammo with GE HealthCare's systems is expected to accelerate the adoption of AI-driven breast cancer screening, benefiting both RadNet and other healthcare providers [4][5]